title: Effect of antibiotics, levofloxacin and fosfomycin, on a mouse model with Escherichia coli O157 infection.
abstract: There have been some reservations about the treatment of enterohemorrhagic Escherichia coli (EHEC) infection with antibiotics to prevent the occurrence of hemolytic uremic syndrome (HUS). However, the administration of antimicrobial agents for EHEC infection is under discussion. Therefore, we used an experimental mouse model to assess the advantage/disadvantage of two major antibiotics, levofloxacin (LVFX) and fosfomycin (FOM). Germ-free IQI mice were inoculated with EHEC O157 strain EDL931 or #7. Bacteria colonized feces at 10(9)-10(10) CFU/g, and Shiga toxins (STXs) were detected in the feces. From 1 day after infection, mice were assigned to LVFX (20 mg/kg) once daily or FOM (400 mg/kg) once daily. A significant decrease in overall mortality was observed after treatment of LVFX, with EHEC disappearing immediately from the feces of mice. FOM also reduced mortality for one strain, the STX level decreased gradually. LVFX exhibited higher therapeutic efficacy than FOM. Strain differences were observed in the model during the treatment.
authors.affiliation: Department of Preventive Dentistry, Health Sciences University of Hokkaido, Japan. emiko@hoku-iryo-u.ac.jp
authors.forename: E
authors.initials: E
authors.lastname: Isogai
authors.forename: H
authors.initials: H
authors.lastname: Isogai
authors.forename: S
authors.initials: S
authors.lastname: Hayashi
authors.forename: T
authors.initials: T
authors.lastname: Kubota
authors.forename: K
authors.initials: K
authors.lastname: Kimura
authors.forename: N
authors.initials: N
authors.lastname: Fujii
authors.forename: T
authors.initials: T
authors.lastname: Ohtani
authors.forename: K
authors.initials: K
authors.lastname: Sato
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001427:Bacterial Toxins / Q000378:metabolism; D003967:Diarrhea / Q000382:microbiology; D004195:Disease Models, Animal; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000382:microbiology; D019453:Escherichia coli O157 / Q000187:drug effects* / Q000302:isolation & purification / Q000378:metabolism; D005243:Feces / Q000382:microbiology; D005578:Fosfomycin / Q000627:therapeutic use*; D005856:Germ-Free Life; D006801:Humans; D064704:Levofloxacin; D051379:Mice; D015242:Ofloxacin / Q000627:therapeutic use*; D022603:Shiga Toxins; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001427:Bacterial Toxins; D022603:Shiga Toxins; D005578:Fosfomycin; D064704:Levofloxacin; D015242:Ofloxacin